Skip to content

US · BCPC · CHEMICALS - SPECIALTY

Balchem Corp (BCPC) intrinsic value and stock valuation

$163.54as of 2026-11-21 · Mkt cap 5.74B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Balchem Corp DCF and intrinsic value

InvestorsCraft values BCPC with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from BCPC’s statements →

Balchem Corp Graham Number

Graham Number: $64.19d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Basic Materials · Chemicals - Specialty Montvale, NJ 07645 balchem.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.04B+8.1% 5y CAGRd
20112025
Net income
$154.8M+12.8% 5y CAGRd
20112025
Free cash flow
$173.1M+8.2% 5y CAGRd
20112025
Total equity
$1.26B+8.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.04B$953.7M$922.4M$942.4M$799M
Operating income$218.3M$182.9M$159.2M$145.2M$127.5M
Net income$154.8M$128.5M$108.5M$105.4M$96.1M
EPSd$4.75M$3.93M$3.34M$3.25M$2.94M
Operating cash flow$216.6M$182M$183.8M$138.5M$160.5M
Capital expenditure-$-43.49M-$-35.66M-$-37.89M-$-50.29M-$-37.45M
Free cash flow$173.1M$146.3M$145.9M$88.3M$123.1M
Total assets$1.71B$1.58B$1.6B$1.62B$1.2B
Total debt$192M$208M$330.3M$460.6M$118M
Net debt$117.4M$158.5M$265.9M$394.1M$14.8M
Total equity$1.26B$1.15B$1.05B$938.3M$877M
Cash and short-term investments$74.6M$49.5M$64.5M$66.6M$103.2M
Income statement
20252024202320222021
Revenue$1.04B$953.7M$922.4M$942.4M$799M
Cost of revenue$666.5M$617.5M$620.4M$661.9M$555.9M
Gross profit$370.6M$336.2M$302.1M$280.5M$243.2M
Research and development expenses$18.5M$16.8M$15.1M$12.2M$13.5M
Selling, general and administrative expenses$142.8M$136.5M$130.1M$123.1M$102.2M
Other expenses-$-9.01M$0.00-$-2.32M$0.00$0.00
Operating expenses$152.3M$153.3M$142.9M$135.3M$115.7M
Cost and expenses$818.8M$770.8M$763.3M$797.2M$671.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$10.2M$16.5M$22.6M$10.3M$2.46M
Depreciation and amortization$45.2M$48M$54.9M$51.9M$48.9M
Ebitda$254.4M$231M$214.8M$195.9M$176.6M
Operating income$218.3M$182.9M$159.2M$145.2M$127.5M
Total other income/expenses, net-$-19.3M-$-16.46M-$-21.93M-$-11.44M-$-2.27M
Income before tax$199M$166.5M$137.3M$133.8M$125.2M
Income tax expense$44.2M$38M$28.7M$28.4M$29.1M
Net income$154.8M$128.5M$108.5M$105.4M$96.1M
Weighted average shares outstanding$32.6M$32.3M$32.1M$32M$32.2M
Weighted average diluted shares outstanding$32.6M$32.7M$32.5M$32.4M$32.7M
Balance sheet
20252024202320222021
Cash and short-term investments$74.6M$49.5M$64.5M$66.6M$103.2M
Net receivables$143.6M$119.7M$125.3M$131.6M$117.4M
Inventory$131.5M$130.8M$109.5M$119.7M$91.1M
Total current assets$365.6M$313.8M$314.2M$335.8M$322.2M
Property, plant and equipment, net$322.8M$299.2M$295.9M$290.8M$246.8M
Goodwill and intangible assets$979.7M$945.1M$970.1M$982.8M$618.6M
Long-term investments$3.72M$3.86M$4.08M$4.29M-$-46.45M
Total non-current assets$1.34B$1.26B$1.28B$1.29B$877.1M
Total assets$1.71B$1.58B$1.6B$1.62B$1.2B
Accounts payable$60.4M$54.7M$55.5M$57.3M$56.2M
Short-term debt$3.82M$3.33M$4.22M$4.02M$2.36M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$176.4M$157.7M$148.5M$140M$143.8M
Long-term debt$188.2M$204.7M$326.1M$456.6M$115.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$273.8M$267.8M$394.7M$546.2M$178.5M
Capital lease obligations$12.9M$18M$20.8M$20M$9.47M
Total liabilities$450.2M$425.5M$543.2M$686.2M$322.3M
Common stock$2.14M$2.17M$2.15M$2.15M$2.15M
Retained earnings$1.12B$997.5M$897.5M$814.5M$732.1M
Accumulated other comprehensive income (loss)$41.6M-$-23.75M$8.69M-$-7.15M-$-4.99M
Total equity$1.26B$1.15B$1.05B$938.3M$877M
Total investments$3.72M$3.86M$4.08M$4.29M-$-46.45M
Total debt$192M$208M$330.3M$460.6M$118M
Net debt$117.4M$158.5M$265.9M$394.1M$14.8M
Cash flow statement
20252024202320222021
Net income$154.8M$128.5M$108.5M$105.4M$96.1M
Depreciation and amortization$45.7M$48M$54.9M$51.9M$48.9M
Stock-based compensation$18.1M$16.7M$16.1M$13.2M$10.8M
Change in working capital-$-7.46M-$-6.12M$20M-$-25.22M$10.9M
Accounts receivable-$-20.85M$5.58M$6.97M-$-3.62M-$-20.7M
Inventory$3.63M-$-22.79M$10.5M-$-7.8M-$-21.02M
Accounts payable$11.3M$9.06M$3.55M-$-15.54M$46.2M
Net cash provided by operating activities$216.6M$182M$183.8M$138.5M$160.5M
Investments in property, plant and equipment-$-43.49M-$-35.66M-$-37.89M-$-50.29M-$-37.45M
Acquisitions, net-$-50K-$-24.16M-$-1.54M-$-365.78M$320K
Net cash used for investing activities-$-43.89M-$-59.74M-$-34.81M-$-416.01M-$-35.3M
Common stock issued$9.31M$0.00$0.00$0.00$0.00
Common stock repurchased-$-107.64M-$-5.68M-$-4.47M-$-35.42M-$-35.24M
Dividends paid-$-28.29M-$-25.58M-$-22.87M-$-20.71M-$-18.72M
Net cash used for financing activities-$-152.81M-$-133.81M-$-153.32M$246.7M-$-102.18M
Net change in cash$25.1M-$-14.93M-$-2.11M-$-36.68M$18.7M
Cash at end of period$74.6M$49.5M$64.5M$66.6M$103.2M
Operating cash flow$216.6M$182M$183.8M$138.5M$160.5M
Capital expenditure-$-43.49M-$-35.66M-$-37.89M-$-50.29M-$-37.45M
Free cash flow$173.1M$146.3M$145.9M$88.3M$123.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Balchem Corp

        Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

        CEO
        Theodore L. Harris
        Employees
        1.35K
        Beta
        0.81

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Balchem Corp (BCPC)?

        Balchem Corp (BCPC) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BCPC undervalued?

        BCPC trades at a price of $163.54 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.